Drug Approval | February 24, 2024
Orchid Pharma's 'Exblifep' receives USFDA approval
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
The launch of a DGCA Type Approved Logistics Drone facilitates critical medical deliveries to remote regions
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
iSolveSM information on demand is the result of our focus on customer relationship
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
_256_384.png){kind=logo}
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
Subscribe To Our Newsletter & Stay Updated
